Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mehmet Altan

Showing results (111-120 of 153) with videos related to

Pageof 16
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLCJames W Welsh, John V Heymach, Chunxiao Guo, et al.
Nature Medicine|April 25, 2018
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancerJacqulyne P Robichaux, Yasir Y Elamin, Zhi Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2025
Safety and Tolerability of Lete-cel in NSCLC-ReplyMehmet Altan, Gilberto Lopes, T Jeroen N Hiltermann, et al.
JTO Clinical and Research Reports|March 31, 2025
Longitudinal Tracking of <i>ALK</i>-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNASimon Heeke, Saumil Gandhi, Hai T Tran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2024
Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung CancerMehmet Altan, Gilberto Lopes, T Jeroen N Hiltermann, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 29, 2019
Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLCSteven H Lin, Yan Lin, Luyang Yao, et al.
Journal for Immunotherapy of Cancer|October 24, 2020
Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom InventoryTito Mendoza, Ajay Sheshadri, Mehmet Altan, et al.
Lung Cancer (Amsterdam, Netherlands)|December 10, 2025
A multi-institutional perspective on tarlatamab administration and management of CRS/ICANSBingnan Zhang, Laura Alder, Samuel Rosner, et al.
Nature Medicine|August 20, 2024
Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancerJacqulyne P Robichaux, Yasir Y Elamin, Zhi Tan, et al.
Scientific Reports|August 23, 2022
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical TrialTito R Mendoza, David S Hong, Christine B Peterson, et al.
Pageof 16

Showing results (111-120 of 153) with videos related to

Sort By:
Pageof 16
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLCJames W Welsh, John V Heymach, Chunxiao Guo, et al.
Nature Medicine|April 25, 2018
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancerJacqulyne P Robichaux, Yasir Y Elamin, Zhi Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2025
Safety and Tolerability of Lete-cel in NSCLC-ReplyMehmet Altan, Gilberto Lopes, T Jeroen N Hiltermann, et al.
JTO Clinical and Research Reports|March 31, 2025
Longitudinal Tracking of <i>ALK</i>-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNASimon Heeke, Saumil Gandhi, Hai T Tran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2024
Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung CancerMehmet Altan, Gilberto Lopes, T Jeroen N Hiltermann, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 29, 2019
Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLCSteven H Lin, Yan Lin, Luyang Yao, et al.
Journal for Immunotherapy of Cancer|October 24, 2020
Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom InventoryTito Mendoza, Ajay Sheshadri, Mehmet Altan, et al.
Lung Cancer (Amsterdam, Netherlands)|December 10, 2025
A multi-institutional perspective on tarlatamab administration and management of CRS/ICANSBingnan Zhang, Laura Alder, Samuel Rosner, et al.
Nature Medicine|August 20, 2024
Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancerJacqulyne P Robichaux, Yasir Y Elamin, Zhi Tan, et al.
Scientific Reports|August 23, 2022
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical TrialTito R Mendoza, David S Hong, Christine B Peterson, et al.
Pageof 16